HOME > COMMENTARY
COMMENTARY
-
COMMENTARY 3 articles
June 19, 2006
-
Predicting the Future Market for Smoking Cessation Aids: Will OTC Products Continue to Outsell Ethical Products?
June 5, 2006
-
Major Domestic Companies Invest More Than Ever in R&D
May 29, 2006
-
Incident in PI Trial in UK 5 articles
May 8, 2006
-
COMMENTARY 3 articles
April 24, 2006
-
New Prescription Form Shaking Things Up at Pharmacies
April 24, 2006
-
Proposed Increases in Frequency of NHI Price Revisions
April 17, 2006
-
JMA Needs to Establish New Partnership with LDP
April 17, 2006
-
COMMENTARY 4 articles
April 3, 2006
-
Tougher Pricing Policy, New Products Essential to Offset Impact of NHI Price Revision
March 27, 2006
-
No Domestic Company Moves Despite Expected Growth: Vaccine Business
March 27, 2006
-
FY2006 NHI Price Revision: Industry Succeeds in Defensive Efforts
March 13, 2006
-
Pfizer Management, Labor See Signs of Snowbreak
March 6, 2006
-
Effects of Medical Fee Revision Need to be Verified
March 6, 2006
-
<COMMENTARY> New Dispensing Fees Nearly Decided
February 20, 2006
-
Japan's Most Admired Pharma Companies P. Reed Maurer
February 20, 2006
-
Requirements for External IRBs to Be Relaxed
February 13, 2006
-
Frustrating Outcome for Industry: Exceptional NHI Price Reduction for Long-listed Drugs
February 13, 2006
-
Astellas' Inventorship Issue with Professor Ochiai - What If This Were a US Case?
February 6, 2006
-
COMMENTARY 2 articles
January 30, 2006
ページ
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…